Trials / Completed
CompletedNCT01892137
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 137 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this trial is to demonstrate the predictive value of the clinical diagnosis of clearance of Actinic Keratoses after treatment with Ingenol Mebutate using histopathological examination as the standard.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ingenol mebutate gel 0.05% | Once daily for 2 consecutive days |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-03-01
- Completion
- 2014-05-01
- First posted
- 2013-07-04
- Last updated
- 2025-02-24
Locations
10 sites across 2 countries: Australia, Germany
Source: ClinicalTrials.gov record NCT01892137. Inclusion in this directory is not an endorsement.